Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen® Designed to Treat Patients with Dry-AMD

Business Wire October 6, 2014

BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares

Business Wire October 6, 2014

BioTime's Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute

Business Wire October 3, 2014

LifeMap Solutions Adds Chief Technology Officer to Leadership Team

Business Wire October 1, 2014

Asterias Biotherapeutics Announces Distribution Date of BioTime Warrants and Conversion Date of Series B Common Stock into Series A Common Stock

Business Wire September 29, 2014

BioTime, Inc.'s Subsidiary OncoCyte Corporation's CEO Dr. Joseph Wagner to Present at BTIG's Inaugural "Emerging Technologies in Healthcare Diagnostics" Symposium

Business Wire September 19, 2014

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen® in Preclinical Animal Studies

Business Wire September 17, 2014

BioTime, Inc.'s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development

Business Wire September 15, 2014

BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer

Business Wire September 11, 2014

Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer

PR Newswire September 11, 2014

BioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference

Business Wire September 9, 2014

Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock

PR Newswire September 4, 2014

BioTime Inc. (BTX) Drops 5.14% on September 2

Equities.com September 2, 2014

BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem®-Based Hydrogel for Vocal Fold Scarring

Business Wire August 28, 2014

BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients With Cervical Complete Spinal Cord Injury

Business Wire August 27, 2014

Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury

PR Newswire August 27, 2014

BioTime Inc. (BTX) Jumps 6.50% on August 26

Equities.com August 26, 2014

Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast

PR Newswire August 25, 2014

Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution

PR Newswire August 21, 2014

BioTime Receives FDA Premarket Notification Clearance for Premvia(TM) 510(k)

Business Wire August 12, 2014